RATIONALE: Disruption of epidermal tight junctions (TJs), is thought to promote immunological responses to epicutaneous antigens. The Atopic Dermatitis Research Network performed a cross-sectional study to visualize TJs and Langerhans cells (LCs) in the skin of atopic dermatitis (AD) and nonatopic (NA) controls. METHODS: Epidermal sheets were isolated from nonlesional, upper extremity skin taken from 8 S. aureus colonized (ADStaph+), 10 non-colonized (ADStaph-) AD subjects and 9 NAStaph-. These whole mounts were stained for the TJ protein (occludin) and markers of LCs/dendritic cells (DCs) (CD207 [Langerin] and HLA-DR). Images were captured with a confocal microscope and analyzed in a blinded manner using Imaris software. RESULTS: Greater than 97% of epidermal DCs were LCs, with no differences observed between AD and NA. More epidermal LCs (HLA-DR+/CD207+) were present in AD skin (33.261.8 per 0.04mm 2 ), compared to NA skin (26.362.8 per 0.04mm 2 , p50.043). The occludin staining could be categorized into four distinct patterns with the fragmented pattern observed more commonly in AD (49%) vs NA (20%). Notably, LCs clustered in the immediate region around the fragmented TJs, expressed high levels of HLA-DR and had greater dendricity. Staph colonization did not significantly affect these observations. CONCLUSIONS: LCs are more numerous in nonlesional AD skin. This is the first demonstration that even the nonlesional skin of AD subjects frequently has an abnormal TJ appearance and that this is spatially associated with greater number of activated LCs. These findings suggest that LCs from nonlesional AD skin behave as though they are reacting to TJ disruption.
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The Protective Effects of Eosinophilia and High IgE on Cancer Diagnoses in the National Health and Nutrition Examination Surveys (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) Sairaman Nagarajan, MD, MPH New York Medical College, Valhalla, NY. RATIONALE: Cetuximab is a monoclonal antibody to epidermal growth factor receptor primarily used as adjunctive treatment of metastatic cancers. Hypersensitivity reactions, including anaphylaxis, and especially in the southeastern part of the United States, are one of the most wellknown adverse effects of cetuximab. The aim of this meta-analysis is to gain better insight into the overall incidence of cetuximab-induced hypersensitivity reactions. METHODS: Databases including PubMed, EMBASE, the Cochrane library, American Society of Clinical Oncology, and Web of Science were searched to identify relevant studies. Eligible studies identified were randomized to prospective comparator phases II and III trials of patients with cancer treated with cetuximab. The primary endpoint was the incidence of hypersensitivity reactions. RESULTS: Fourteen studies were identified, including a total of 6047 patients available for analysis. 2,991 patients received cetuximab, and 3,056 patients did not. The risk ratio of grades 3 or 4 hypersensitivity reactions was found to be 2.45 (95% CI; 1.85-3.24). There were 154 grade 3 or 4 hypersensitivity reactions in the cetuximab group, and 61 grade 3 or 4 hypersensitivity reactions in the non-cetuximab group. The risk ratio of any hypersensitivity reaction (Grades 1-4) was 5.47 (95% CI; 3.80-7.87) with 337 hypersensitivity reactions in those treated with cetuximab, and 96 in those not treated with the drug. CONCLUSIONS: Treatment regimens that include cetuximab are associated with a significant risk of hypersensitivity reactions including grade 3 and 4 hypersensitivity reactions. Pretreatment with anti-cetuximab antibody titers should be considered before starting this medication.
